I see that some are pointing to DXB as a comparison, (I used to be in DXB, but made my money and got out) but DXB, while it has an awesome and important product, doesn't have:
phase 3 trial results;
FDA approval;
A product that is already selling in another jurisdiction;
strong sales results there;
a sales team and support network ready to go and primed for success.
DXB does have Nina, and she is brilliant.
BOT, as I have said before, will paddle its own canoe.
The CR may be an inconvenience for some, but it is seriously only a blip, but it is, as has been pointed out by others, an important step in maximising any return from any buyout that may appear on the horizon.
I see that some are pointing to DXB as a comparison, (I used to...
-
- There are more pages in this discussion • 199 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.025(7.46%) |
Mkt cap ! $567.0M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 33.3¢ | $14.94M | 42.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 112268 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 276101 | 7 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |